Company Description
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics.
The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women’s health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand.
It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology lab services, kits and reagents.
In addition, the company is involved in research and development activities; and provision of procurement, warehousing, product development, and staffing management services.
It serves research organizations, corporations, independent laboratories, large hospital systems and public and private institutions, as well as distributor customers.
The company operates in the United Kingdom, the United States, and China. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021.
Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
| Country | United Kingdom |
| Founded | 2013 |
| IPO Date | Jul 21, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | James Foster |
Contact Details
Address: BioCity Glasgow, Bo’Ness Road Newhouse Lanarkshire, ML1 5UH United Kingdom | |
| Phone | 44 20 7788 7414 |
| Website | viraxbiolabs.com |
Stock Details
| Ticker Symbol | VRAX |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001885827 |
| CUSIP Number | G9495L109 |
| ISIN Number | KYG9495L1251 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| James Foster | Chairman, Chief Executive Officer and Principal Accounting Officer |
| Dr. Nigel McCracken M.Sc., Ph.D. | Chief Operating Officer and Director |
| Clement Monteil | Head of Scientific Research and Development |
| Lily Fu | Head of Supply Chain |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 30, 2025 | 6-K | Report of foreign issuer |
| Jul 2, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Jun 13, 2025 | 6-K | Report of foreign issuer |
| Mar 18, 2025 | 6-K | Report of foreign issuer |
| Mar 13, 2025 | 6-K | Report of foreign issuer |
| Mar 5, 2025 | 6-K | Report of foreign issuer |
| Feb 25, 2025 | 6-K | Report of foreign issuer |
| Jan 30, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 23, 2024 | 6-K | Report of foreign issuer |
| Dec 17, 2024 | 6-K | Report of foreign issuer |